Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
POSTER: MM-1484 DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features
María‐Victoria Mateos, Paweł Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Kihyun Kım, Meletios A Dimopoulos, Claudio Cerchione, Nick Pirooz, Astrid McKeown, Chee Paul Lin, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opa, Vânia Hungria (2025). POSTER: MM-1484 DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01370-9.
Article48 days agoPOSTER: MM-1485 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir Vorobyev, Michèle Cavo, Kazuhito Suzuki, Paweł Robak, Kristin Morris, Chee Paul Lin, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Brandon E. Kremer, MariaVictoria Mateos, Meletios A Dimopoulos (2025). POSTER: MM-1485 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01371-0.
Article48 days agoEfficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.
Marcelo Pitombeira de Lacerda, Meletios A Dimopoulos, Luděk Pour, Kihyun Kim, Sergey Voloshin, Hanlon Sia, Esther González, Chang‐Ki Min, Anna Sureda, Ivan Spicka, Paweł Robak, Marek Hus, Vera Zherebtsova, Merit Hanna, Vinay Jadhav, Nicholas Pirooz, Ianire Garrobo-Calleja, Lydia Eccersley, Vânia Hungria, Meral Beksaç (2025). Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7548.
Article48 days agoMM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir Vorobyev, Michèle Cavo, Kazuhito Suzuki, Paweł Robak, Kristin Morris, Chee Paul Lin, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Brandon E. Kremer, MariaVictoria Mateos, Meletios A Dimopoulos (2025). MM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02742-9.
Article48 days agoMM-1484: DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features
María‐Victoria Mateos, Paweł Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Kihyun Kım, Meletios A Dimopoulos, Claudio Cerchione, Nick Pirooz, Astrid McKeown, Chee Paul Lin, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opa, Vânia Hungria (2025). MM-1484: DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02741-7.
Article48 days ago